Haemonetics Corporation $HAE Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in shares of Haemonetics Corporation (NYSE:HAE) by 125.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,334 shares of the medical instruments supplier’s stock after acquiring an additional 28,586 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.11% of Haemonetics worth $2,893,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of HAE. AQR Capital Management LLC increased its position in Haemonetics by 48.6% during the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after purchasing an additional 1,034,226 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after purchasing an additional 1,254,035 shares during the period. North Peak Capital Management LLC increased its position in shares of Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after acquiring an additional 740,626 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Haemonetics by 2.5% during the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after acquiring an additional 26,763 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Haemonetics by 17.3% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after acquiring an additional 124,020 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HAE has been the subject of several recent analyst reports. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research report on Friday, June 26th. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Finally, Mizuho boosted their price objective on Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $78.33.

Haemonetics Trading Up 0.0%

Shares of NYSE HAE opened at $75.04 on Wednesday. The business has a 50-day moving average price of $67.43 and a two-hundred day moving average price of $66.37. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The firm has a market capitalization of $3.41 billion, a PE ratio of 37.15, a PEG ratio of 1.51 and a beta of 0.52. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the prior year, the firm earned $1.24 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts predict that Haemonetics Corporation will post 5.22 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.